Dr. Bindu Paul's lab at Johns Hopkins University is studying how hydrogen sulfide, a gas produced in the brain, protects against neurodegeneration, particularly in Alzheimer's disease. The team aims to uncover the specific molecules and pathways that are affected by hydrogen sulfide, which could lead to new therapies for age-related brain diseases. Their research combines molecular biology techniques with behavioral studies in mouse models to explore these protective mechanisms.

Dr. Payam Mohassel's research lab focuses on understanding how disruptions in lipid metabolism, particularly involving sphingolipids, contribute to motor neuron diseases like amyotrophic lateral sclerosis (ALS). By using cellular and animal models, the lab investigates the effects of specific genetic mutations on neuronal health and explores potential therapeutic strategies to mitigate these effects. Their work aims to reveal new insights into neurodegeneration and develop targeted treatments for ALS.

Dr. Richard L Huganir's lab at Johns Hopkins University focuses on understanding how the brain encodes memories through the study of AMPA receptors, which are crucial for synaptic transmission and plasticity. The lab uses innovative techniques such as two-photon microscopy and biotinylation to visualize and analyze the interactions of synaptic proteins during learning and memory processes in live mice. Their research aims to uncover the molecular mechanisms underlying various brain disorders and to identify potential therapeutic targets for conditions like Alzheimer's, schizophrenia, and autism.

Dr. Solange P Brown's lab at Johns Hopkins University studies how a brain region called the claustrum helps us make flexible decisions, especially under changing circumstances. They use animal models to investigate how the claustrum interacts with other brain areas critical for cognition, particularly when we need to learn from our past choices. By understanding these brain mechanisms better, the research aims to shed light on cognitive flexibility, which is often impaired in various neuropsychiatric disorders like schizophrenia and ADHD.

Dr. James J. Knierim's lab explores the role of the hippocampus in learning and memory, particularly how its function may change with aging and in conditions like Alzheimer's disease. Using rodent models, the lab studies how different parts of the hippocampus contribute to memory processing and how age-related changes impact cognitive functions. Their research aims to uncover mechanisms underlying memory deficits to help develop potential therapeutic interventions for age-related cognitive decline.

Dr. Kyrana Tsapkini's lab focuses on developing innovative treatments for language impairments associated with atypical Alzheimer's disease, particularly in patients suffering from logopenic variant primary progressive aphasia (lvPPA). Using a method called transcranial direct current stimulation (tDCS), they aim to enhance the effectiveness of speech-language therapy and improve cognitive functions like memory. Their research explores how targeted brain stimulation can help mitigate cognitive deficits and generalize language treatment benefits for those affected by this condition.

The Tsukamoto Lab at Johns Hopkins University is focused on developing new treatments for Alzheimer's disease by targeting an enzyme called neutral sphingomyelinase 2 (nSMase2). This research aims to inhibit the production of harmful molecules that contribute to Alzheimer's pathology, potentially slowing the disease's progression. By optimizing new drug candidates and testing them in animal models, the lab hopes to find effective therapies that can improve outcomes for patients suffering from Alzheimer's.

The lab of Dr. Seung-Wan Yoo at Johns Hopkins University focuses on understanding the interactions between HIV and methamphetamine use, and how these lead to increased neuroinflammation and cognitive impairments. By using advanced models like iPSC-derived microglia and humanized mice, the lab investigates the molecular mechanisms involved, particularly the role of a protein called MECOM. The ultimate goal is to identify potential therapeutic targets that can help mitigate neurological issues faced by individuals living with HIV and substance use disorders.